AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04204356 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Language treatment for improving discourse production
Description: All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
Study NCT04204356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language treatment for improving discourse production
Description: All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
Study NCT04204356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
Study NCT03874390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozone
Description: gaseous ozone was applied on periodontal pocket two times in one week.
Study NCT04091373 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the upper arm
Study NCT05502276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection (ESD)
Description: Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
Study NCT03874390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: gaseous ozone was applied on periodontal pocket two times in one week.
Study NCT04555876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone external muscle stimulation- stationary bicycle
Description: high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
Study NCT03550040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Surgical removal of the prostate
Study NCT03550040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: Surgical removal of the prostate
Study NCT01005875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Nexavar in bottles of 120 tables
Study NCT01005875 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT
Study NCT03312075 — intervention group
Intervention type: OTHER
Intervention: Sputum and blood samples
Description: The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
Study NCT00195702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
Study NCT00195702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
Study NCT00195702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
Study NCT00195702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
Study NCT00195702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
Study NCT00195702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
Study NCT00309192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intravitreal Injection 4mg single dose
Study NCT00309192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Grid laser
Description: Grid laser as specified in ETDRS
Study NCT00309192 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Grid laser
Description: Grid laser as specified in ETDRS
Study NCT00309192 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Simulation procedure for triamcinolone injection
Study NCT02095028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention
Description: participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
Study NCT02683330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Description: MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
Study NCT04091373 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the lower abdomen
Study NCT02416466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CEA CAR-T cells
Description: Gene modified patient T cells.
Study NCT02416466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sir-Spheres
Description: SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
Study NCT02698917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaCO2
Description: 4.5-4.7 kPa
Study NCT04091373 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the thigh
Study NCT02517632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, nutritional and pharmaceutical counceling
Description: The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
Study NCT02517632 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional and pharmaceutical counceling
Description: The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
Study NCT01159600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI 10773 high dose
Description: Placebo tablets matching BI 10773 high dose
Study NCT02920723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Study NCT02698917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaCO2
Description: 5.8-6.0 kPa
Study NCT02698917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2
Description: 10-15 kPa
Study NCT02698917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaO2
Description: 20-25 kPa
Study NCT02698917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: 65-75 mmHg
Study NCT02698917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: 80-100 mmHg
Study NCT03961529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% OPA-15406 ointment
Description: Twice daily
Study NCT03961529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406 ointment
Description: Twice daily
Study NCT03830463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Single oral dose
Study NCT03830463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study NCT01159600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI 10773 low dose
Description: Placebo tablets matching BI 10773 low dose
Study NCT01159600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily high dose open label
Study NCT01159600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily high dose
Study NCT01159600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI 10773 low dose
Description: Placebo tablets matching BI 10773 low dose
Study NCT01159600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily low dose
Study NCT01159600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI 10773 high dose
Description: Placebo tablets matching BI 10773 high dose
Study NCT00963924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
Study NCT03695510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Oral Tablet
Description: 40mg oral, daily, continuously
Study NCT03695510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: 200mg, intra-venous injection, every 3 weeks, for 35 cycles
Study NCT01154621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
Study NCT02920723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study NCT02965885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
Study NCT01154621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 5% dextrose solution
Study NCT03371628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
Study NCT02994160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast electrode
Description: Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
Study NCT00625859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
Study NCT03759444 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
Study NCT04098172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Guidewire
Description: Fractional Flow Reserve measurement
Study NCT05563441 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
Study NCT03198585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Capsule, once a day for 90 days
Study NCT03198585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, once a day for 90 days
Study NCT02113891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant).
Study NCT01939067 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Heated Humidified High Flow Nasal Cannula
Description: Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
Study NCT01939067 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Continuous Positive Airway Pressure
Description: Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
Study NCT04225104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yogic breathing intervention
Description: Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
Study NCT03323736 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Iontophoresis & tube placement
Description: Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
Study NCT03323736 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tube placement
Description: Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
Study NCT00649831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulinic acid
Description: amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
Study NCT00649831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
Study NCT01650740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg daily x 1 week followed by 60 mg daily
Study NCT01650740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
Study NCT01650740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study visits only
Description: Weekly visits x 4 weeks followed by visits every 2 weeks
Study NCT01912690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic training
Study NCT01912690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic and strength training
Study NCT00471887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
Study NCT04437992 — intervention group
Intervention type: GENETIC
Intervention: NIPT
Description: The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
Study NCT02442258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.
Study NCT02442258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.
Study NCT00006094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00006094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00006094 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy
Study NCT04870541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
Study NCT04870541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam Injectable Solution
Description: Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
Study NCT03330184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride group
Study NCT03330184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium group
Study NCT03330184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride and Bifidobacterium group
Study NCT03330184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03951909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy activity and awareness intervention: PAAI
Description: 10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
Study NCT03951909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention: Teaching recovery techniques (TRT)
Description: TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
Study NCT01936493 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: At a future time DNA analysis will be performed
Study NCT01936493 — intervention group
Intervention type: OTHER
Intervention: Hormonal analysis
Description: Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
Study NCT05455801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: negative preassure wound therapy
Description: wound treated with negative pressure therapy dressing
Study NCT02606357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form:Solution~Route of administration: Subcutaneous